Literature DB >> 28602367

Heart Failure with Preserved Ejection Fraction in Older Adults.

Bharathi Upadhya1, Dalane W Kitzman2.   

Abstract

Most elderly patients, particularly women, who have heart failure, have a preserved ejection fraction. Patients with this syndrome have severe symptoms of exercise intolerance, frequent hospitalizations, and increased mortality. Despite the importance of heart failure with preserved ejection fraction (HFpEF), the understanding of its pathophysiology is incomplete, and optimal treatment remains largely undefined. Unlike the management of HFrEF, there is a paucity of large evidence-based trials demonstrating morbidity and mortality benefit for the treatment of HFpEF. An update is presented on information regarding pathophysiology, diagnosis, management, and future directions in this important and growing disorder.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Comorbidities; Elderly; Heart failure; Preserved ejection fraction

Mesh:

Year:  2017        PMID: 28602367      PMCID: PMC5546159          DOI: 10.1016/j.hfc.2017.02.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  145 in total

1.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.

Authors:  Sripal Bangalore; Sanobar Parkar; Ehud Grossman; Franz H Messerli
Journal:  Am J Cardiol       Date:  2007-08-10       Impact factor: 2.778

2.  The HFpEF Obesity Phenotype: The Elephant in the Room.

Authors:  Dalane W Kitzman; Sanjiv J Shah
Journal:  J Am Coll Cardiol       Date:  2016-07-12       Impact factor: 24.094

3.  Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial.

Authors:  Ali Ahmed; Bertram Pitt; Shahbudin H Rahimtoola; Finn Waagstein; Michel White; Thomas E Love; Eugene Braunwald
Journal:  Int J Cardiol       Date:  2007-03-23       Impact factor: 4.164

4.  Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry.

Authors:  Urban Alehagen; Lina Benson; Magnus Edner; Ulf Dahlström; Lars H Lund
Journal:  Circ Heart Fail       Date:  2015-01-09       Impact factor: 8.790

5.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

6.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.

Authors:  Wojciech Kosmala; David J Holland; Aleksandra Rojek; Leah Wright; Monika Przewlocka-Kosmala; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2013-07-31       Impact factor: 24.094

Review 8.  The role of IL-1 in the pathogenesis of heart disease.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

9.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

10.  Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure.

Authors:  Dirk Westermann; Alexander Riad; Utz Richter; Sebastian Jäger; Konstantinos Savvatis; Mirjam Schuchardt; Nora Bergmann; Markus Tölle; Dirk Nagorsen; Michael Gotthardt; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Basic Res Cardiol       Date:  2009-03-03       Impact factor: 17.165

View more
  22 in total

1.  The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart.

Authors:  Lydia E Matesic; Lisa A Freeburg; Laura B Snyder; Lauren-Ashley Duncan; Amber Moore; Paige E Perreault; Kia N Zellars; Edie C Goldsmith; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-08-21       Impact factor: 4.733

2.  Mechanoregulation of Myofibroblast Fate and Cardiac Fibrosis.

Authors:  Peter Kim; Nick Chu; Jennifer Davis; Deok-Ho Kim
Journal:  Adv Biosyst       Date:  2017-12-04

Review 3.  Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction.

Authors:  Gilman D Plitt; Jordan T Spring; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-07-16

4.  Advanced maternal age impacts physiologic adaptations to pregnancy in vervet monkeys.

Authors:  Maren Plant; Cecilia Armstrong; Alistaire Ruggiero; Chrissy Sherrill; Beth Uberseder; Rachel Jeffries; Justin Nevarez; Matthew J Jorgensen; Kylie Kavanagh; Matthew A Quinn
Journal:  Geroscience       Date:  2020-06-25       Impact factor: 7.713

Review 5.  Transforming growth factor-β in myocardial disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2022-01-04       Impact factor: 32.419

6.  Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity.

Authors:  Bochra Tourki; Vasundhara Kain; Saame Raza Shaikh; Xavier Leroy; Charles N Serhan; Ganesh V Halade
Journal:  FASEB J       Date:  2020-06-16       Impact factor: 5.191

Review 7.  Impaired Exercise Tolerance in Heart Failure: Role of Skeletal Muscle Morphology and Function.

Authors:  Wesley J Tucker; Mark J Haykowsky; Yaewon Seo; Elisa Stehling; Daniel E Forman
Journal:  Curr Heart Fail Rep       Date:  2018-12

8.  Left ventricular diastolic dysfunction in patients with obesity hypoventilation syndrome.

Authors:  Hadil A Al Otair; Fayez Elshaer; Alaa Elgishy; Samar Z Nashwan; Aljohara S Almeneessier; Awad H Olaish; Ahmed S BaHammam
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 9.  Salivary Biomarkers for Diagnosis and Therapy Monitoring in Patients with Heart Failure. A Systematic Review.

Authors:  Aidonis Rammos; Aris Bechlioulis; Petros Kalogeras; Evanthia E Tripoliti; Yorgos Goletsis; Anna Kalivi; Effrosyni Blathra; Pietro Salvo; M Giovanna Trivella; Tommaso Lomonaco; Roger Fuoco; Francesca Bellagambi; Chris J Watson; Abdelhamid Errachid; Dimitrios I Fotiadis; Lampros K Michalis; Katerina K Naka
Journal:  Diagnostics (Basel)       Date:  2021-05-02

Review 10.  Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF).

Authors:  Emmanuel Eroume A Egom
Journal:  Front Physiol       Date:  2021-05-21       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.